ABBV: Robust pipeline and strategic deals drive growth in immunology, neuroscience, and oncology
Strong growth in immunology, neuroscience, and oncology is driven by a robust pipeline, strategic acquisitions like Apogee, and innovative combination therapies. Market expansion is expected in atopic dermatitis, asthma, Parkinson’s, and multiple myeloma, with significant near-term catalysts and a…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.